Related Experiment Video
Updated: Jun 27, 2026

Virtual Agent for Real-Time Motivational Interviewing by Integrating Adaptive Nonverbal Behavior and Language Models
Published on: December 23, 2025
Are new agents really making a difference in MDS?
1Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. rstone@partners.org
Abstract:
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow stem cell disorders characterized by dysplastic hypercellular marrows with peripheral cytopenias. The Leukemia & Lymphoma Society estimates the annual US incidence of MDS is at least 12,000. MDS occurs primarily in people over 60 years old. The pathophysiology of most subtypes of MDS is poorly understood. Treating MDS remains a challenge despite the availability of new agents, such as lenalidomide, azacitidine, and decitabine. Whether these drugs have made a real difference in treating this group of diseases remains controversial.
Related Concept Videos
Healthcare Agencies II
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources, and lay...
Healthcare Agencies I
Clinical Significance of Antibiotic Resistance
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Documentation in Long-Term and Home Healthcare Setting
Long-Term Care Facilities
Community Based Intervention
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...

